Business
Scilex Holding Company Announces Launching of Co-Pay Programs for Both ZTlido® and ELYXYB® for Commercially Insured Patients and the addition of ELYXYB® to a Multi-State Medicaid Pharmaceutical Purchasing Group to Its Purchasing Pool
Launching Co-Pay programs for ZTlido® and ELYXYB® for commercially insured patientsMulti-State Medicaid Pharmaceutical Purchasing Group added ELYXYB® to its
About this update from Scilex Holding Company
[{"type":"text","content":"Launching Co-Pay programs for ZTlido® and ELYXYB® for commercially insured patientsMulti-State Medicaid Pharmaceutical Purchasing Group added ELYXYB® to its purchasing pool PALO ALTO, Calif., April 09, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today announced launching of co-pay programs for both ZTlido® and ELYXYB® with the out-of-pocket costs for its product portfolio for commercially insured patients capped at $25 monthly, with certain eligible patients paying as low as $0. This applies to the Company's postherpetic neuralgia pain product, ZTlido®, and migraine product, ELYXYB®. Scilex has made significant investments to improve patient affordability and access to its products and continues to build on the Company's commitment to provide non-opioid pain management products to patients. Additionally, on April 1, 2024, a multi-state Medicaid pharmaceutical purchasing group added ELYXYB® to its purchasing pool to make it eligible for thirteen States’ Medicaid programs. Scilex believes that high deductibles and co-pay programs should not prevent patients from receiving the medications they need. Scilex co-pay programs are designed to help patients reduce their co-pay and out-of-pocket costs for their medications. Our program partners with various assistance programs to help make patient medications more affordable. For more information on the ZTlido® co-pay program, refer to https://www.ztlido.com/getting-started/ and for the ELYXYB® co-pay program, refer to https://www.elyxyb.com/savings. For more information on Scilex Holding Company, refer to www.scilexholding.com For more information on ZTlido® including Full Prescribing Information, refer to www.ztlido.com. For more information on ELYXYB®, including Full Prescribing Information, refer to www.elyxyb.com. For more information on Gloperba®, including Full Prescribing Information, refer to www.gloperba.com. https://www.facebook.com/scilex.pharm https://www.linkedin.com/company/scilex-holding-company/ [email protected] About Scilex Holding Company Scilex Holding Company is an innovative revenue-generating company focused on acquiring, developing and commercia...